Yahoo Finance Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) instance, it's good news for shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
See our latest analysis for Mineralys Therapeutics
Mineralys Therapeutics Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider purchase was by CFO, Chief Business Officer & Secretary Adam Levy for US$100k worth of shares, at about US$16.00 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$6.27). Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
While Mineralys Therapeutics insiders bought shares during the last year, they didn't sell. They paid about US$14.13 on average. These transactions suggest that insiders have considered the current price attractive. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insiders At Mineralys Therapeutics Have Bought Stock Recently
There was some insider buying at Mineralys Therapeutics over the last quarter. CEO & Director Jon Congleton bought US$27k worth of shares in that time. It's great to see that insiders are only buying, not selling. But in this case the amount purchased means the recent transaction may not be very meaningful on its own.
Insider Ownership Of Mineralys Therapeutics
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Mineralys Therapeutics insiders own 3.4% of the company, worth about US$8.8m. Whilst better than nothing, we're not overly impressed by these holdings.
So What Do The Mineralys Therapeutics Insider Transactions Indicate?
Our data shows a little insider buying, but no selling, in the last three months. That said, the purchases were not large. However, our analysis of transactions over the last year is heartening. We'd like to see bigger individual holdings. However, we don't see anything to make us think Mineralys Therapeutics insiders are doubting the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Mineralys Therapeutics has 4 warning signs (2 are a bit concerning!) that deserve your attention before going any further with your analysis.
Of course Mineralys Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
